eEnergy Group PLC (LON:EAAS) was 8% brighter at 6.61p after revenue for the ten weeks to September 11 rocketed 250% to £4mln.
The AIM-listed company, which provides energy efficiencies services, saw a “significant” uplift in new business wins and installation momentum, boosted by installation from contracts won before and during lockdown worth over £1mln.
The board expects to achieve breakeven profit after tax for the six months to December 31.
1pm: Surgical Innovations slides on discounted placing
Its an 11% discount to Wednesdays closing price.
The minimally invasive surgery firm said the fundraise is being arranged within its existing non pre-emptive authority so it will not need shareholder approval.
11.10am: Nostra Terra Oil & Gas jumps after Pine Mills project update
Nostra Terra Oil & Gas Company PLC (LON:NTOG) gushed 30% higher to 0.36p after announcing drilling operations at the Pine Mills project in Texas will begin in October.
The oiler farmed out the undeveloped area to Cypress Minerals in April and now holds a 32.5% working interest.
Next, the operator is preparing to construct the drilling pad, followed by mobilizing the rig and spudding the new well.
10.10am: WANdisco slips on lower full-year revenue forecast
WANdisco plc (LON:WAND) was a mid-morning faller, with a 12% slip to 504p after admitting full-year revenue will be below expectations but it is forecast to be at least US$35mln in 2021.
In the six months to June 30, revenue dropped 40% to US$3mln while underlying loss widened 56% to US$11mln, though cash at period-end was US$33mln.
The data company noted during the pandemic it has seen an accelerated business shift towards cloud systems.
Revenue slumped 35% to £42mln in the six months to June but the windows and doors parts manufacturer noted it has seen strong customer demand since the restart of operations in May.
The operational challenges linked to recovery and growth have adversely impacted customer service levels post-lockdown so it is investing to address this rapidly.
9pm: ThinkSmart an early riser after strong full-year results
The specialist digital payments platform business saw its profit after tax soar 513% to £53mln driven by a non-cash fair value gain on an independent valuation of its 10% shareholding in Clearpay Finance.
Clearpay, which provides "Buy Now Pay Later" services in the UK, had 1mln customers signed up in its first 12 months of trading to end June.
Elsewhere, Tiziana Life Sciences PLC (NASDAQ:TLSA)(LON:TILS) advanced 7% to 156.88p after revealing it will conduct a clinical study to study the nasally administered Foralumab in coronavirus (COVID-19) patients in Brazil.
It will be assessed either alone or in combination with orally administered dexamethasone.
The biotech said the candidate can help modulate the human immune system to suppress a possible “cytokine storm”, often seen in COVID-19 patients, and to potentially reduce respiratory failure.
Proactive news headlines:
Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) has signed an agreement to use its “potentially transformative” approach to modulating the immune system in a human clinical study of patients with coronavirus (COVID-19). Work will get underway in Brazil starting next month, with the company's drug, Foralumab, administered by nasal spray either on its own or in combination with an orally-taken anti-inflammatory called dexamethasone. Tiziana has moved straight into human trials because it had already secured safety data for the nasal application for the drug from a phase I clinical assessment carried out a year ago.
Eden Research PLC (LON:EDEN) has announced that its commercial collaborator, Eastman Chemical Company has received authorisation for the sale of its Cedroz product in France. The AIM-quoted company, which is focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, said the French regulator has also approved Eden's biofungicide, Mevalone, for use in organic agriculture in France. Separately, the group added, it has been notified that Mevalone has received authorisation for use on table and wine grapes in Serbia via regional distributor K&N Efthymiadis (KNE).
OptiBiotix Health PLC (LON:OPTI) said its subsidiary ProBiotix Health has signed an exclusive distribution agreement for Brazil with local group Ayalla Marketing. The UK companys new partner will distribute the cholesterol-reducing probiotic, LPLDL, both as an ingredient and as four finished products – CholBiome, CholBiomeX3, CholBiomeBP and CholBiome. OptiBiotix said the deal offered an “agreed and expected” first order within 30 days from approval by the Brazilian authorities of its food technology.
FastForward Innovations Ltd, the AIM-quoted company focused on making investments in fast-growing and industry-leading businesses, has noted that its investee company Juvenescence Limited has signed a partnership deal with Evgen Pharma PLC.FastForward has around a 0.63% interest in the issued stock of Juvenescence. In a statement on Wednesday, Juvenescence – a life sciences company focused on modifying ageing and increasing human healthspan – said Evgen has licensed its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Supermarket Income REIT PLC (LON:SUPR) has said it is to raise £150mln to take advantage of opportunities that have become available since the onset of coronavirus restrictions. The trust invests in sites occupied by the major supermarket chains such as Tesco, Sainsburys, Morrisons and Waitrose and has identified £400mln worth of omnichannel sites that meet its criteria of size and online fulfilment potential. Property funds having to meet redemptions are one source of sites, it said, and due diligence has already been carried out on three worth £135mln in total. The REIT also announced it was increasing its dividend target for 2021 to 5.86p after raising the dividend by 4% to 5.8p in the year to June just ended.